WUXI APPTEC - An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section

does not make any representation about the accuracy or completeness of this announcement and expressly disclaims any liability arising out of or in connection with all or any part of this announcement. We are not responsible for any losses caused by reliance on such content.

WUXI APPTEC CO., LTD.* Wuxi WuXi AppTec New Drug Development Co., Ltd.

(a joint stock limited company incorporated in the People's Republic of China) (Stock code: 2359)

Overseas Regulatory Announcements

This overseas regulatory announcement is made by the Company in accordance with Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited

Section 13.10B is made.

The full Chinese text of the following information published by the Company on the Shanghai Stock Exchange website is hereby provided for reference only.

By order of the board of directors Wuxi WuXi AppTec New Drug Development Co., Ltd. Chairman

Dr. Li Ge

Hong Kong, June 11, 2026

As of the date of this announcement, the Company's Board of Directors includes executive directors Dr. Li Ge, Dr. Chen Minzhang, Dr. Yang Qing and Mr. Zhang Zhaohui; Non-executive directors Mr. Tong Xiaoyi and Dr. Wu Yibing; and independent non-executive directors Ms. Lu Shaohua, Dr. Yu Wei, Dr. Zhang Xin, Ms. Zhan Zhiling and Mr. Leng Xuesong.

*For identification only

Securities code: 603259 Securities abbreviation: WuXi AppTec Announcement number: Lin 2026-023

Wuxi WuXi AppTec New Drug Development Co., Ltd.

Regarding the repurchase of A shares, the top ten shareholders and the top ten shareholders without selling restrictions

Announcement of shareholding status

The company's board of directors and all directors guarantee that there are no false records or misleading statements in this announcement. or major omissions, and assume legal responsibility for the authenticity, accuracy and completeness of its content.

Wuxi WuXi AppTec New Drug Development Co., Ltd. (hereinafter referred to as the "Company") in June 2026

The third meeting of the fourth session of the Board of Directors was held on the 9th, and the "About the Centralized Bidding Transactions in 2026" was reviewed and approved.

Proposal to repurchase the company's A shares. For details, please refer to the company’s announcement on Shanghai Securities on June 10, 2026

"About the repurchase of A-shares through centralized bidding transactions in 2026" disclosed on the exchange website and designated media "Repurchase Report" (Announcement No.: Pro 2026-022).

According to the "Share Repurchase Rules of Listed Companies" and "Self-Discipline Supervision Guidelines for Listed Companies of the Shanghai Stock Exchange"

No. 7 - Repurchase of Shares" and other relevant regulations, the company's board of directors will now disclose the transaction before the resolution to repurchase shares. The names of the top ten shareholders and the top ten shareholders without selling restrictions as of June 9, 2026

The name, number of shares held and shareholding ratio are announced as follows:

Number of shares held Shareholding ratio Shares Serial number The names of the top ten shareholders and the top ten shareholders without selling restrictions (Share) (%) Type 1 HKSCCNOMINEESLIMITED 510,434,758 17.11 H shares 2 Hong Kong Securities Clearing Company Limited 239,757,368 8.04 A shares 3 G&CVILimited 127,309,054 4.27 A shares 4 G&CIVHongKongLimited 93,135,472 3.12 A shares Beijing Zhongmin Yinfu Investment Management Co., Ltd.-Jiaxing Yu 5 77,511,585 2.60 A shares Xiang Investment Partnership (Limited Partnership) 6 G&CVLimited 65,076,978 2.18 A shares China Construction Bank Co., Ltd.-E Fund Shanghai and Shenzhen 7 300 Medical and health trading open-end index securities investment 37,998,189 1.27 A shares fund

8 G&CVIILimited 33,696,017 1.13 A shares Bank of China Co., Ltd. - Huabao CSI Medical Exchange 9 32,432,352 1.09 A shares Easy open-end index securities investment fund SUMMERBLOOMINVESTMENTS(I) 10 31,721,901 1.06 A shares PTE.LTD.

Note:

1. The top ten shareholders of the company are consistent with the top ten shareholders subject to no selling limit.

2. "Shareholding ratio" is calculated based on the company's total share capital of 2,983,757,155 shares as of the date of this announcement. "Type of shares"

Among them, A-shares refer to RMB common stocks, and H-shares refer to overseas-listed foreign-invested stocks.

3. HKSCCNOMINEESLIMITED is Hong Kong Securities Clearing Company (Agents) Limited, and its shares are Held on behalf of multiple clients; Hong Kong Securities Clearing Company Limited is the nominal holder of Shanghai-Hong Kong Stock Connect RMB ordinary shares.

Announcement is hereby made.

Board of Directors of Wuxi WuXi AppTec New Drug Development Co., Ltd.

June 12, 2026